Anthony Marl, DO
Internal Medicine · Charlotte, MINPI 1689694671
Payments from drug & device makers
Across 92 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$340
- AbbVie$249
- Pfizer$162
- Merck$99
- GSK$74
- Lilly USA, LLC$71
- plus $415 from 15 others
What the payments were for
- Food & beverage$1,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $340 |
| AbbVie(2 entities) | 15 | $249 |
| Pfizer | 9 | $162 |
| Merck | 6 | $99 |
| GSK | 6 | $74 |
| Lilly USA, LLC | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| AstraZeneca | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Novartis | 2 | $35 |
| Astellas Pharma US Inc | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Exact Sciences | 1 | $16 |
| Amgen | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,410 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 77 | $121,470 |
| EliquisApixaban | 101 | $115,963 |
| OzempicSemaglutide | 79 | $103,008 |
| JardianceEmpagliflozin | 42 | $64,207 |
| XareltoRivaroxaban | 56 | $60,808 |
| RybelsusSemaglutide | 20 | $37,942 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $29,680 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $27,793 |
| MyrbetriqMirabegron | 23 | $26,468 |
| JanuviaSitagliptin Phosphate | 17 | $25,496 |
| TradjentaLinagliptin | 23 | $21,571 |
| EntrestoSacubitril/Valsartan | 16 | $21,483 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $20,386 |
| FarxigaDapagliflozin Propanediol | 13 | $19,735 |
| Repatha SureclickEvolocumab | 18 | $17,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $340 | $140,95099 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $71 | $135,68591 claims |
| PfizerEliquis, Lyrica | $162 | $123,000113 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $26 | $101,93084 claims |
| Johnson & JohnsonXarelto | $13 | $60,80856 claims |
| MerckJanuvia, Janumet | $99 | $39,08235 claims |
| AstraZenecaFarxiga, Symbicort | $47 | $32,43944 claims |
| GSKTrelegy Ellipta | $74 | $27,79328 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $26,46823 claims |
| NovartisEntresto | $35 | $21,48316 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $8,68112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Charlotte
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.